Pacira BioSciences (PCRX) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, gaining 55.4% versus a gain of 2.4%. Over five years, SNDX leads with a -9.1% price change compared with -31.6% for PCRX. Syndax Pharmaceuticals is the larger company by market cap ($1.51 billion vs $1.45 billion), about 1.0 times the size.
Pacira BioSciences converts more of its revenue into profit, with a net margin of 1.0% versus -165.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PCRX | SNDX |
|---|---|---|
| Share price | $36.39 | $16.90 |
| Market cap | $1.45B | $1.51B |
| 1-day change | +44.40% | -0.76% |
| YTD return | +40.61% | -19.56% |
| 1-year return | +55.45% | +2.42% |
| 5-year return | -31.60% | -9.09% |
| P/E ratio (TTM) | 103.97 | — |
| Forward P/E | 10.52 | — |
| EPS (TTM) | $0.35 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $726.41M | $172.35M |
| Revenue growth (YoY) | +3.63% | +627.84% |
| Net income (latest FY) | $7.03M | $-285.42M |
| Gross margin | 79.39% | — |
| Operating margin | 2.64% | -158.45% |
| Net margin | 0.97% | -165.60% |
| 52-week high | $36.46 | $25.59 |
| 52-week low | $18.80 | $12.99 |
| Distance from 52-week high | -0.19% | -33.96% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -17.26% | +122.19% |
| Average volume | 1.03M | 1.55M |
| Shares outstanding | 39.86M | 89.30M |
| Employees | 825 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCRX has outperformed SNDX by 53.0 percentage points over the past year.
- Pacira BioSciences is more profitable, keeping 1.0 cents of every revenue dollar as net income versus -165.6 cents for Syndax Pharmaceuticals.
- Syndax Pharmaceuticals grew revenue faster in its latest fiscal year (+627.84% vs +3.63%).
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
PCRX vs SNDX FAQ
Which is bigger, Pacira BioSciences or Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) is larger, with a market capitalization of $1.51B compared with $1.45B for Pacira BioSciences (PCRX).
Which stock has performed better over the past year, PCRX or SNDX?
PCRX returned +55.45% over the past 12 months, compared with +2.42% for SNDX (price return, excluding dividends). Past performance does not predict future results.
Are Pacira BioSciences and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.